News | August 19, 2025
Pfizer’s sickle cell disease candidate fails Phase III trial
Inclacumab was generally well tolerated in THRIVE-131
Inclacumab was generally well tolerated in THRIVE-131
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase
The new facility will enhance AbbVie’s chemical synthesis capacity to support domestic production of current and next-generation neuroscience, immunology, and oncology medicines
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
_256_384.jpg)
Marksans Pharma gets USFDA nod for acid reflux drug
AINU is set to accelerate its expansion footprint, enhance operational capabilities
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
Minister releases five breakthrough veterinary technologies to strengthen diagnostics and combat antimicrobial resistance
Subscribe To Our Newsletter & Stay Updated
